Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Perturbagen Concentration | Perturbagen Conc Unit | Biological Replicate ID | Relative Cell Count | Normalized Growth Rate Inhibition Value | Nominal Division Rate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HCC38 | TNBC | Basal B | MG-132 | Proteasome | Proteasome | 2.67 | uM | 11850.145 | 0.0113 | -0.7518 | 2.1492 | |
| HCC1187 | TNBC | Basal A | NSC 663284 | CDC25 | CDC | 33.3 | uM | 10753.152 | 0.0113 | -0.9245 | 1.3690 | |
| SK-BR-3 | HER2amp | Luminal | Fascaplysin | CDK4 | CDK | 33.3 | uM | 7526.084 | 0.0113 | -0.8320 | 1.8115 | |
| HCC3153 | TNBC | Basal A | Temsirolimus | MTOR | MTOR | 133 | uM | 10937.144 | 0.0113 | -0.8900 | 1.5466 | |
| MDA-MB-134-VI | HR+ | Luminal | Chloroquine | 66.5 | uM | 12662.177 | 0.0113 | -0.8553 | 1.7065 | |||
| HCC1143 | TNBC | Basal A | NSC 663284 | CDC25 | CDC | 33.3 | uM | 12112.159 | 0.0113 | -0.8205 | 1.8609 | |
| MDA-MB-361 | HER2amp | Luminal | Vinorelbine | TUBB | TUBB | 46.4 | uM | 7896.042 | 0.0113 | -0.9577 | 1.1632 | |
| SUM52PE | HR+ | Luminal | Lestaurtinib | FLT3/JAK2/TrkA | RTK | 33.3 | uM | 11852.154 | 0.0113 | -0.9393 | 1.2816 | |
| 184B5 | NM | Basal | Oxaliplatin | DNA cross-linker | DNA cross-linker | 629 | uM | 9095.119 | 0.0113 | -0.9485 | 1.2263 | |
| HCC1187 | TNBC | Basal A | Bortezomib | Proteasome | Proteasome | 66.7 | uM | 15300.203 | 0.0113 | -0.9901 | 0.8443 | |
| HCC1954 | HER2amp | Basal A | Omipalisib | PI3K | PI3K | 33.3 | uM | 10469.087 | 0.0113 | -0.8807 | 1.5889 | |
| SUM185PE | TNBC | Luminal | NSC 663284 | CDC25 | CDC | 33.3 | uM | 12269.152 | 0.0113 | -0.9878 | 0.8791 | |
| MCF12A | NM | Basal B | MG-132 | Proteasome | Proteasome | 13.3 | uM | 14164.189 | 0.0113 | -0.9933 | 0.7884 | |
| MCF 10F | NM | - | NU6102 | CDK1/2 | CDK | 66.7 | uM | 12254.147 | 0.0113 | -0.9129 | 1.4316 | |
| MCF12A | NM | Basal B | Topotecan | TOP1 | TOP | 21.8 | uM | 7491.078 | 0.0113 | -0.9959 | 0.7238 | |
| BT-549 | TNBC | Basal B | Bortezomib | Proteasome | Proteasome | 0.533 | uM | 14723.203 | 0.0113 | -0.8364 | 1.7902 | |
| BT-483 | HR+ | Luminal | Afatinib | EGFR/HER2 | ErbB | 66.7 | uM | 11855.158 | 0.0113 | -0.9969 | 0.6941 | |
| HCC1187 | TNBC | Basal A | Bortezomib | Proteasome | Proteasome | 66.7 | uM | 15300.203 | 0.0113 | -0.9901 | 0.8443 | |
| MCF 10A | NM | Basal B | MG-132 | Proteasome | Proteasome | 13.3 | uM | 11056.145 | 0.0114 | -0.5859 | 2.8383 | |
| HCC1954 | HER2amp | Basal A | Bortezomib | Proteasome | Proteasome | 13.3 | uM | 14735.203 | 0.0114 | -0.7742 | 2.0496 | |
| BT-549 | TNBC | Basal B | LBH589 | HDAC | HDAC | 33.3 | uM | 12305.167 | 0.0114 | -0.5767 | 2.8814 | |
| T47D | HR+ | Luminal | Bortezomib | Proteasome | Proteasome | 66.7 | uM | 15340.203 | 0.0114 | -0.9095 | 1.4449 | |
| HBL-100 | Unknown | Unknown | Doxorubicin | TOP2 | TOP | 0.69 | uM | 9226.034 | 0.0114 | -0.6379 | 2.6175 | |
| T47D | HR+ | Luminal | Bortezomib | Proteasome | Proteasome | 66.7 | uM | 15340.203 | 0.0114 | -0.9095 | 1.4449 | |
| T47D | HR+ | Luminal | LBH589 | HDAC | HDAC | 1.33 | uM | 10939.154 | 0.0114 | -0.8589 | 1.6876 |